FrançaisWest Pharmaceutical Services (WST): financial analysis & fundamentals
📈 See the interactive version (live chart) →
Valuation & profitability
| Metric | Value | What it means |
|---|---|---|
| P/E (price / earnings) | 44.8 | The higher, the more growth the market expects. |
| Forward P/E | 34.7 | On next year's expected earnings. Lower than current P/E = rising earnings. |
| PEG (P/E ÷ growth) | 2.48 | Below 1 = cheap given growth; above 2 = expensive. |
| Net margin | 17% | Share of revenue that ends up as profit. |
| Revenue growth | 14% | Pace of revenue growth. |
| Price-to-book | 8.1 | Price relative to book value. |
| Market cap | $24.4 B | Total market value of the company. |
| Dividend yield | 0.24% | Annual dividend ~$0.87/share relative to price. |
Income statement (by year)
| Year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2022 | $2.9 B | $586 M | 20% |
| 2023 | $2.9 B | $593 M | 20% |
| 2024 | $2.9 B | $493 M | 17% |
| 2025 | $3.1 B | $494 M | 16% |
📊 Open the interactive West Pharmaceutical Services page (charts, live news) →
Frequently asked questions
Is West Pharmaceutical Services stock expensive?
West Pharmaceutical Services has a P/E of 44.8 (forward P/E 34.7) and a PEG of 2.48. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: expensive (the market prices high growth).
What is West Pharmaceutical Services's net margin?
West Pharmaceutical Services's net margin is about 17% — the share of revenue that ends up as net profit.
What is West Pharmaceutical Services's revenue?
Latest known revenue: $3.1 B for net income of $494 M. The year-by-year breakdown is in the income statement above.
What is West Pharmaceutical Services's market cap?
West Pharmaceutical Services (WST) has a market cap of about $24.4 B.
Does West Pharmaceutical Services pay a dividend?
Yes: West Pharmaceutical Services pays about $0.87/share per year, i.e. roughly a 0.24% yield at the current price.
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Data: Yahoo Finance, recomputed by JPI Invest. A stock can be « cheap » for a bad reason.